Low-density lipoprotein cholesterol (LDLC), also known as ‘bad cholesterol,’ contributes to plaque buildup in the arteries and causes damage, making it a ‘silent killer’ ...
Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...
Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.
Meanwhile, Merck & Co is hoping that its daily oral PCSK9 drug MK-0616 will find a role, as it can be dosed alongside current cholesterol drugs like statins. Early trials suggest it as efficacy ...